Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study
Open Access
- 1 April 2005
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 7 (2) , 177-182
- https://doi.org/10.1215/s1152851704000183
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11Neuro-Oncology, 2004
- Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.2003
- Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.2002
- Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate.Journal of Neuro-Oncology, 2002
- A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.2001
- A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.2001
- Phase II Study of Antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in Patients With Recurrent GliomaMayo Clinic Proceedings, 1999
- Increased 9-aminocamptothecin dose requirements in patients on anticonvulsantsCancer Chemotherapy and Pharmacology, 1998
- Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuroblastoma cellsInternational Journal of Cancer, 1995
- Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.Journal of Clinical Investigation, 1993